Surprisingly, 13/28 patients with an initial diagnosis of HERneg breast cancer and 11/18 patients with an initial diagnosis of HER2low breast cancer also fell into the group with high probability, suggesting that the analysis of HER2+EVs from plasma may provide important information beyond the histopathological analysis of tumour biopsies. The gene discussed is ERBB2; the disease is breast carcinoma.